T1	Participants 223 337	21 patients with coronary artery disease who were receiving placebo, acebutolol, and propranolol in a double-blind
T2	Participants 513 553	26 patients with chronic angina pectoris
T3	Participants 981 1020	13 patients with stable angina pectoris
T4	Participants 1272 1341	patients with coronary disease and a wide range of ejection fractions
T5	Participants 1426 1468	reduced resting left ventricular function.
